Bio-Techne Corp (TECH)
NASDAQ · Healthcare · Biotechnology
Bio-Techne Corp is a Healthcare company with a market capitalization of $11.27B, a trailing P/E ratio of 103.3, and a dividend yield of 0.44%.
5-Year Price History
Latest Annual Financials · FY ending June 30, 2025
Recent Quarterly Earnings (EPS)
| Quarter | Reported | Actual EPS | Estimate | Surprise |
|---|---|---|---|---|
| Q3 2026 | May 6, 2026 | $0.53 | $0.53 | +0.0% |
| Q2 2026 | February 4, 2026 | $0.46 | $0.43 | +7.0% |
| Q1 2026 | November 5, 2025 | $0.36 | $0.36 | +0.0% |
| Q4 2025 | August 6, 2025 | $0.53 | $0.50 | +6.0% |
| Q3 2025 | May 7, 2025 | $0.56 | $0.51 | +9.8% |
| Q2 2025 | February 5, 2025 | $0.42 | $0.39 | +7.7% |
Short Interest
FINRA-reported short interest for semi-monthly settlement dates, published about nine business days after each settlement. Share counts are adjusted to the current split basis.
| Settlement | Shares Short | % of Shares Out | Days to Cover | Change |
|---|---|---|---|---|
| July 15, 2026 | 12,123,448 | 7.72% | 2.3 | -23.8% |
| June 30, 2026 | 15,915,631 | 10.14% | 1.5 | -12.6% |
| June 15, 2026 | 18,204,307 | 11.60% | 6.2 | +31.5% |
| May 29, 2026 | 13,846,089 | 8.82% | 5.0 | -4.9% |
| May 15, 2026 | 14,553,011 | 9.27% | 3.7 | +9.1% |
| April 30, 2026 | 13,338,470 | 8.50% | 6.7 | -4.7% |
| April 15, 2026 | 14,001,926 | 8.92% | 7.1 | -0.7% |
| March 31, 2026 | 14,099,778 | 8.98% | 6.7 | +14.1% |
Other Biotechnology Stocks
Frequently Asked Questions
What is Bio-Techne Corp's market cap?
As of August 13, 2026, Bio-Techne Corp (TECH) has a market capitalization of $11.27B.
What is Bio-Techne Corp's P/E ratio?
Bio-Techne Corp trades at a trailing price-to-earnings (P/E) ratio of 103.3. Its forward P/E is 34.5.
Does Bio-Techne Corp pay a dividend?
Yes — Bio-Techne Corp pays a dividend yielding 0.44%, an annual payout of $0.32 per share.
What sector is TECH in?
Bio-Techne Corp is in the Healthcare sector, specifically the Biotechnology industry.
What is Bio-Techne Corp's short interest?
As of the July 15, 2026 FINRA settlement, 12,123,448 TECH shares were sold short, or 7.72% of shares outstanding. Days to cover: 2.3. FINRA publishes short interest twice a month, about nine business days after each settlement date.
What was Bio-Techne Corp's revenue?
In its latest reported fiscal year (ending June 30, 2025), Bio-Techne Corp reported revenue of $1.22B and net income of $73.40M.
Ask your own questions about TECH
Try mrmarket.ai freeData as of August 13, 2026. Figures are sourced from company filings and market data and may be delayed or revised. For informational purposes only — not investment advice.